LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Aclara developed microfluidic lab-on-a-chip technology with applications for genomics, high-throughput drug screening and clinical diagnostics. The company’s technology substantially enlarged throughput capacity while dramatically lowering costs compared with competing approaches. The cornerstone of Aclara’s product development strategy was a disposable plastic or glass “chip” called a LabCard that enabled the computerized control of the movement, measurement and mixing of liquids without the use of moving parts or valves.
Aclara Biosciences
Mountain View, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.